跳至主要内容
临床试验/NCT05852158
NCT05852158招募中4 期

The Use of Single Dose vs Short-Term Peri-Operative Cefazolin in the Prevention of Surgical Site Infection Following Orthognathic Surgery

Abdul El-Rabbany1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2024年1月9日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
400
试验地点
1
主要终点
Surgical Site Infection Rate

研究概览

简要总结

Orthognathic surgery describes a group of procedures aimed at correcting developmental or acquired deformities of the jaws and facial skeleton. The goal of these procedures is to improve speech, jaw and dental function, aesthetics, and symptoms of sleep apnea. This is accomplished by surgical repositioning of the upper jaw (maxilla) and lower jaw (mandible). The most common procedures are lefort I osteotomies (upper jaw repositioning) and bilateral sagittal split osteotomies (lower jaw repositioning). At our institution, almost all cases include one or both of these two procedures. The majority of cases include bilateral sagittal split osteotomies (BSSO). As access to the jaws is through the oral cavity, these procedures are considered to be clean-contaminated surgeries due to the high intra-oral bacterial load. The result is that surgical site infections (SSIs) occur in 10-15% of cases. Studies show that the vast majority of these infections occur in the lower jaw (BSSO sites), presumably due to pooling of saliva and debris. SSIs are associated with patient discomfort, prolonged hospital stays, increased morbidity, and increased cost to healthcare systems.

The use of peri-operative antibiotics has been shown to significantly reduce the incidence of SSI following orthognathic surgery. There is currently no consensus on the dosing or specific antibiotic to be used. There is strong evidence that pre-operative antibiotics significantly decrease SSI compared to no antibiotics. However, to date, there is no good evidence to support the use of post-operative antibiotics to further decrease the rate of infection. Several studies have examined the use of post-operative antibiotics ranging between 1-7 days. The majority of studies were not able to demonstrate a statistically significant difference to justify the use of post-operative antibiotics. A systematic review by Danda and Ravi in 2011 suggested that there likely is a benefit to the use of post-operative antibiotics. Danda and colleagues in 2017 later conducted a trial comparing pre-operative antibiotics alone compared to pre-operative combined with post-operative antibiotics. A statistically significant difference was not found, however, they felt that this was due to a limited sample size. Overall, there is no robust data that supports the use of post-operative antibiotics. The World Health Organization guidelines currently recommend against the use of post-operative antibiotics in orthognathic surgery. However, they do comment that there is some weak evidence that suggests its use. It was deemed that this low quality evidence did not outweigh the potential harm of antimicrobial resistance, which results from inappropriate overuse of antibiotics. Antimicrobial resistance is a serious, growing problem which has deadly consequences.

Our current protocol at the QEII Health Sciences Center for peri-operative antibiotic administration is a single pre-operative dose of 2g cefazolin IV, followed by further doses every 8 hours post-operatively for a total of 24 hours (3 post-operative doses). Our study aims to investigate whether there is a need for these additional post-operative doses. If there is a benefit to these additional doses, the research team aims to investigate whether this benefit outweighs the risks. This question is of great importance in order to avoid an unnecessary contribution to antibiotic resistance and unnecessary potential adverse effects.

Participants will be assigned a study number and randomly allocated to one of two groups. Group A will receive a single pre-operative dose of 2g IV cefazolin. Group B will receive a pre-operative dose of 2g IV cefazolin, followed by an additional three doses post-operatively every 8 hours for a total of 24 hours.

Informed consent will be obtained at each participant's pre-operative assessment in the days leading up to the procedure. The participant will then select a group designation from a sufficiently mixed jar, and group A or B will be assigned to their study number.

For each patient, completed procedures will be documented, along with age, sex, smoking status, length of procedures, and complications. Complications including medication adverse reaction (allergy, toxicity, side effects), surgical complications, and any other significant complications related to the medications or deemed to be relevant to infection risk will be documented. Procedures will be carried out in the standard fashion. Patients will receive the same post-operative instructions and will be discharged with a chlorhexidine mouth rinse to be used for two weeks. Patients will return for follow-up at 2 weeks, 4 weeks, and 6 weeks post-operatively. Surgical site infection diagnosis will be made according to the CDC criteria and will be reported as either superficial, deep, or organ/space infections. Date of occurrence, location of infection, and treatment provided will be recorded on a standard form provided to surgeons.

详细描述

Background

Orthognathic surgery describes a group of procedures whose main goal is to correct congenital and acquired dentofacial deformities, thereby improving speech, mastication, aesthetics, and symptoms of sleep apnea. These outcomes may be achieved by surgical repositioning of the maxilla and mandible using a variety of methods, the most common being Lefort I osteotomies, bilateral sagittal split osteotomies, intraoral vertical ramus osteotomies, and functional genioplasty. As access for these methods involves trans-oral approaches, these procedures are considered to be clean-contaminated surgeries due to the high intra-oral bacterial load. As a result, surgical site infection (SSI) rates are reported in the literature to range from 10-15% following orthognathic surgery. SSIs are associated with patient discomfort, prolonged hospital stays, increased morbidity, and increased cost to healthcare systems.

The use of peri-operative antibiotics has been demonstrated to significantly reduce the incidence of SSI following orthognathic surgery. However, there is continued debate regarding the most effective antibiotic protocol, and no consensus regarding timing or specific antibiotic has been achieved. A 1999 study conducted demonstrated a significant difference in SSI rates between patients treated with a single pre-operative dose of antibiotics compared to placebo. A systematic review in 2011 reported that there likely is a benefit to the use of post-operative antibiotics extended for 1-7 days versus a single pre-operative dose. Antibiotic course length was further evaluated in 2016, the investigators demonstrated a significant difference in effectiveness of 3-day courses of antibiotics vs 1-day. However, the number needed to treat was 10, due to which the conclusion was made that the potential harms may not outweigh the risks. Several studies conducted have failed to justify the prolonged use of post-operative antibiotics past 24 hours. As such, it seems that the common standard is the use of pre-operative antibiotics in conjunction with short-term (24-hours or less) post-operative antibiotic courses. To date, few studies have been conducted comparing SSI rates in patients receiving a single pre-operative antibiotic dose to those in patients receiving a pre-operative dose in conjunction with a 24-hour post-operative course. A trial conducted in 2017 found an SSI rate of 9.3% in patients receiving a single pre-operative antibiotic dose compared to 2.6% in patients receiving a pre-operative dose in conjunction with a 24-hour post-operative course, however, the results were not statistically significant. The group attributed this result to an inadequate sample size. In a 2013 study, researchers demonstrated a significant difference in SSI rate between patients receiving a single dose of pre-operative intravenous (IV) Amoxicillin compared to those receiving an additional two doses post-operatively. This, however, is in contrast to several studies which failed to demonstrate a benefit of post-operative antibiotics compared to single pre-operative doses. Overall, there seems to be no robust data supporting the use of post-operative antibiotics following orthognathic surgery. With limited data supporting prolonged antibiotic use, one must question if there are any benefits to offset the risks of antibiotic over-use, which include medication adverse effects, increased healthcare costs, and most importantly, antibiotic resistance. The World Health Organization (WHO) published guidelines recommend no prolongation of antibiotic administration post-operatively following orthognathic surgery, as it was deemed that the low quality evidence supporting its use did not outweigh the potential harm of antimicrobial resistance.

In addition to course length and timing, the choice of antibiotic also plays a major role in SSI rate following orthognathic surgery. The most commonly reported antibiotics used in clinical trials appear to be penicillin, amoxicillin, cefazolin, clindamycin, and ampicillin. A systematic review was conducted in 2019, which reported improved efficacy of cefazolin compared to clindamycin and penicillin in preventing post-orthognathic surgery SSIs.

The most common bacterial isolates from odontogenic infections are Viridans group streptococci, Peptostreptococcus, Prevotella, Fusobacterium, and Bacteroides. Overall, cefazolin has high susceptibility rates against the most common oral bacteria. Cefazolin shows excellent susceptibility rates against Viridans group streptococci, Peptostresptococcus, Prevotella, and Fusobacterium.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Outcomes Assessor)

盲法说明

Surgeons assessing for the presence of surgical site infection will be blinded to the antibiotic regimen that the patient received.

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients ASA 1 and 2 over the age of 16 undergoing orthognathic surgery will be offered participation in this study

排除标准

  • Patients ASA 3 and higher, use of antibiotics in the preceding 2 weeks, presence of systemic, oral, or odontogenic infections, patients in a state of immunosuppression as a result of medications or systemic disease, patients with allergies to penicillins or cephalosporins, and patients who lack capacity for informed consent.

研究组 & 干预措施

Single Dose

Experimental

Single pre-operative dose of 2g IV Cefazolin given prior to first incision for orthognathic surgical procedure

干预措施: Cefazolin 2 GM Injection (Drug)

24-Hour Dosing

Active Comparator

Single pre-operative dose of 2g IV Cefazolin given prior to first incision for orthognathic surgical procedure, as well as 2g IV Cefazolin q8h post-operatively for 24 hours (3 total doses)

干预措施: Cefazolin Injection (Drug)

结局指标

主要结局

Surgical Site Infection Rate

时间窗: 6 weeks

Patients will be evaluated at 2, 4, and 6 weeks post-surgery. Surgical sites will be evaluated for presence of infection. Infections will be classified as superficial, deep, or space infection. This information, along with the location of the infection, will be recorded on a standardized form provided to surgeons. Presence of infection will be reported as "yes" or "no". Type of infection will be reported as "superficial", "deep" or "space". Location will be reported as "right maxilla", "left maxilla", "right mandible", or "left mandible".

次要结局

  • Rate of Medication Adverse Effects(6 weeks)
  • Impact of sex on surgical site infection rate(6 weeks)
  • Impact of surgical complications on surgical site infection rate(6 weeks)
  • Impact of smoking status on surgical site infection rate(6 weeks)
  • Impact of surgery type on surgical site infection rate(6 weeks)
  • Impact of medication adverse effects on surgical site infection rate(6 weeks)
  • Impact of surgery length on surgical site infection rate(6 weeks)

研究者

发起方
Abdul El-Rabbany
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Abdul El-Rabbany

Principal Investigator, Oral and Maxillofacial Surgery Resident

Nova Scotia Health Authority

研究点 (1)

Loading locations...

相似试验